Also Read: Unchained Labs Launches AI Developability Workcell for Biologics R&D 

Underscoring the strategic relevance of scaling high-throughput genomic data on secure cloud infrastructure, Matt Rabinowitz, PhD, executive chairman of MyOme, stated: “Our collaboration with Oracle is an important step toward making predictive genomics available at global scale. Pairing MyOme’s whole-genome platform with OCI’s global infrastructure lets us identify people at high risk for preventable disease early enough to act on it.” Reaffirming the focus on clinical impact and early intervention, Dan Spellman, group vice president, AI and OCI, Healthcare & Life Sciences at Oracle, added: “By making predictive genomics accessible, clinicians have more information to decide on the right intervention at the right time. Together, we’re driving toward a better standard for healthcare globally.” Ultimately, this partnership provides healthcare organizations worldwide with a secure, enterprise-grade infrastructure to deliver personalized, preventive clinical care that reduces long-term treatment costs and improves patient outcomes.

Read More: MyOme and Oracle Collaborate to Advance Genomic Risk Prediction at Global Scale

The post MyOme and Oracle Partner to Advance Global Scale Predictive Genomic Risk Modeling appeared first on ITDigest.

Also Read: Guardant Health Earns FDA Approval for Guardant360 CDx

Highlighting the shift away from legacy workflows, Tim Harkness, Founder and CEO of Unchained Labs, stated: “Developability research has been stuck in the past samples moving from tool to tool, data trapped in different software and scientists left to piece together the answer. The AI Developability Workcell changes all of that. Automation, sample prep, analytics and AI work together from day one so teams can ditch the chaos, stop chasing data and start advancing the right candidates in days instead of weeks.” Ultimately, this platform-native workcell provides biopharmaceutical research organizations with an end-to-end, automated ecosystem that maximizes sample efficiency, standardizes structured data generation, and optimizes early-stage biologic drug development.

Read More: Unchained Labs Puts AI to Work, Debuts Developability Workcell

The post Unchained Labs Launches AI Developability Workcell for Biologics R&D appeared first on ITDigest.

Also Read: Abcam and Genedata Collaborate to Accelerate AI-Driven Antibody Development

Reaffirming the clinical impact of shifting from reactive treatment to proactive ctDNA surveillance, Helmy Eltoukhy, Guardant Health chairman and co-CEO, stated: “This approval represents a landmark shift in how we define disease progression and reinforces the transformative role of liquid biopsy in guiding therapy decisions earlier at a critical moment in a breast cancer patient’s treatment journey.” Representing the 29th global companion diagnostic indication for Guardant360 CDx, this approval reinforces Guardant’s extensive reimbursement footprint across Medicare and commercial payers covering over 300 million lives while establishing circulating tumor DNA monitoring as an essential clinical protocol in precision oncology workflows.

Read More: Guardant Health Announces Landmark FDA Approval of Guardant360^® CDx as Companion Diagnostic for AstraZeneca’s ETCAMAH (camizestrant) in Advanced Breast Cancer

The post Guardant Health Earns FDA Approval for Guardant360 CDx appeared first on ITDigest.

Also Read: Clarivate Expands Agentic AI Across Cortellis Portfolio to Accelerate Drug Development

“As researchers seek high-quality antibodies across a growing range of targets and applications, it is essential that we continue to scale and evolve our development capabilities to meet their needs,” said Kaveh Kahen, PhD, President at Abcam. “By building on Genedata’s world class platform we benefit from automation, connectivity, and flexibility needed to support our global R&D operations. Together, we have created a stronger foundation for data-driven innovation, enabling us to develop and deliver high-quality antibodies more efficiently and create greater value for customers.” Othmar Pfannes, PhD, President of Genedata, said the collaboration will help scientific teams generate actionable insights at scale and establish a foundation for AI-powered discovery, ultimately enabling researchers to access validated reagents faster.

Read More: Abcam and Genedata Collaborate to Accelerate AI-Driven Antibody Development at Global Scale

The post Abcam and Genedata Collaborate to Accelerate AI-Driven Antibody Development appeared first on ITDigest.

In conventional pharmaceutical research, prioritizing candidate compounds presents significant financial and operational risk. Established computer-aided virtual screening methods depend heavily on detailed crystal structures of disease targets, leaving many biologically significant targets inaccessible. AQPotency eliminates this bottleneck by running on standard computing hardware to evaluate molecule-target pairs in seconds at approximately $1 per 1,000 comparisons. Furthermore, the model delivers actionable confidence intervals and domain-of-applicability scores for every prediction, offering clear visibility into result reliability.

“SandboxAQ’s models have been very impactful for our work as we develop new treatments for Parkinson’s,” said Professor Dario R. Alessi, OBE, FMedSci, FRS, Director of the MRC Protein Phosphorylation Unit at the University of Dundee. “These models enable us to explore a much larger biochemical space in a short timeframe and improve both activity and selectivity. SandboxAQ’s unique datasets and models stand out in the industry for their impact.”

Dual-Directional Screening and Structural Flexibility

Beyond standard target-to-molecule scoring, AQPotency features reverse-screening capabilities. Researchers can evaluate a single promising compound against a wide panel of human proteins to generate ranked binding predictions, helping teams uncover mechanisms of action for uncharacterized molecules.

Key functional capabilities of AQPotency include:

Structure-Free Molecular Scoring: Evaluates compound potency across previously unmapped or complex protein targets, expanding discovery efforts beyond traditional 3D crystal structures.

Quantifiable Confidence Metrics: Provides explicit reliability scores alongside each prediction, allowing biopharma teams to allocate laboratory budgets exclusively to high-confidence leads.

Reverse Target Profiling: Scans individual molecules against broad protein panels to identify binding sites and clarify complex biological pathways.

Integrated Cloud Deployment: Connects directly into Claude via MCP, with upcoming enterprise distribution planned for Google Cloud Marketplace.

Also Read: QIAGEN Broadens QIAcuity Digital PCR Portfolio to Drive Biopharma Innovation 

“This collaboration with SandboxAQ highlights the power of combining advanced AI-enabled discovery with rigorous experimental validation to unlock novel opportunities against historically difficult membrane targets. By identifying selective SV2C binders from a broad commercial library, the work establishes a compelling foundation for the development of first-in-class small-molecule tools and future therapeutics aimed at Parkinson’s disease and other disorders of dopaminergic signaling,” said Dr. Gary W. Miller the Adrienne Block Professor of Environmental Health Sciences and the Vice Dean for Research Strategy and Innovation at the Columbia University Mailman School of Public Health.

Andrea Bortolato, Vice President of Drug Discovery, at SandboxAQ, said: “AQPotency has given us and our customers a faster, scalable and reliable way to prioritize compounds in the workflows we already run, without needing a 3D crystal structure of the target. This opens up programs that structure-based methods simply couldn’t reach. The confidence intervals make the output actionable for biopharma companies, and the model has already been successfully used in eight customer programs with experimentally validated impact.”

“What’s compelling about AQPotency is that it makes high-value discovery decisions faster and more practical,” said Robin Roehm, CEO and Co-Founder at Apheris, which offers federated data and AI networks for life science companies. “Researchers can prioritize the most promising compounds with greater confidence, focus experimental resources where they matter most, and expand discovery efforts to targets that have traditionally been harder to pursue.”

Commercial Availability

AQPotency is available immediately via Claude through MCP and SandboxAQ’s main platform, with deployment on Google Cloud Marketplace scheduled to follow. Concurrent with this launch, SandboxAQ has also released AQCat Adsorption Spin, a specialized LQM built to accelerate catalyst discovery within materials science and chemical engineering applications.

The post SandboxAQ Launches AQPotency LQM to Accelerate Early Drug Discovery appeared first on ITDigest.

Also Read: GenScript and Tamarind Bio Partner to Connect AI Molecular Design with Lab Validation 

Contextualizing this paradigm shift, Anne Lecocq, Senior Vice President and General Manager, R&D, Life Sciences & Healthcare, Clarivate, said: “In modern R&D, success depends on how quickly teams can translate complex data into decisive action. Cortellis is advancing this shift with agentic AI, evolving from insight delivery to workflow execution across the product lifecycle. Together, these innovations reflect the evolution of Cortellis from a trusted information source into a connected ecosystem of agentic capabilities that augment human expertise across the R&D lifecycle. Built on trusted data, it empowers teams to reduce friction, align decisions and act with precision in high-stakes environments.” Ultimately, this strategic rollout equips global research organizations to make faster, evidence-based decisions, optimize resource allocation, and accelerate the commercialization of impactful therapeutics.

Read More: Clarivate Scales Agentic AI Across Cortellis to Advance Drug Development

The post Clarivate Expands Agentic AI Across Cortellis Portfolio to Accelerate Drug Development appeared first on ITDigest.

Also Read: Revvity Launches “Signals for Startups” to Empower Early-Stage Biotechs 

“But biology still determines what moves forward. By connecting AI-powered design to experimental proof, this partnership is helping lay the groundwork for the next generation of scientific innovation.” Underscoring the goal of democratizing computational biology and accelerating R&D timelines, “Tamarind was built to make advanced molecular design accessible to every scientist,” said Deniz Kavi, CEO and Co-Founder of Tamarind Bio. “Partnering with GenScript bridges the gap between digital design and physical experimentation, empowering scientists to turn promising candidates into actionable lab results faster than ever.” Ultimately, this connected framework empowers research teams across therapeutics and industrial biotechnology to evaluate candidate molecules faster, build higher-quality datasets, and make better-informed discovery decisions.

Read More: GenScript and Tamarind Bio Partner to Connect AI Molecular Design with Rapid Lab Validation

The post GenScript and Tamarind Bio Partner to Connect AI Molecular Design with Lab Validation appeared first on ITDigest.

Dr. Christensen brings over two decades of experience in drug discovery and development to the CEO role. Prior to joining Terremoto, he served as Chief Scientific Officer at Mirati Therapeutics, where he oversaw discovery, early clinical development, and manufacturing. He also previously held executive leadership roles at Pfizer Oncology, contributing to nonclinical research and translational science for targeted cancer therapies such as Sutent® and Xalkori®.

Also Read: CurifyLabs Raises $14M Series A to Power the Future of Personalized Medicine 

The leadership transition coincides with significant operational milestones for the South San Francisco- and San Diego-based biotechnology firm. Terremoto recently completed a $108 million Series C financing round to advance its pipeline of targeted small-molecule candidates. Additionally, the company secured FDA Fast Track designation for TER-2013, an AKT1-selective small molecule inhibitor targeting breast cancer, and filed an Investigational New Drug (IND) application for TER-4480 in Q3 2026.

Dr. Christensen’s appointment reflects Terremoto’s strategic focus on moving its proprietary pipeline through clinical development while expanding its portfolio of targeted therapeutics. With established funding, regulatory progress, and an experienced leadership team, Terremoto is positioned to accelerate its clinical-stage programs aimed at serious diseases.

The post Terremoto Biosciences Names James Christensen as Chief Executive Officer appeared first on ITDigest.

FB102, Forte Biosciences’ lead program, expands argenx’s portfolio of differentiated immunology medicines, adding a first-in-class anti-CD122 antibody with clinical proof-of-concept in vitiligo and celiac disease and potential to address multiple autoimmune diseases. The acquisition reflects argenx’s disciplined approach to identifying and advancing breakthrough science for patients with the potential to redefine standards of care in diseases that have lacked meaningful innovation for decades.

“Our Vision 2030 strategy is well-defined and on track, and our discovery, development and commercialization engines are delivering real value for patients,” said Karen Massey, Chief Executive Officer of argenx. “The acquisition of Forte Biosciences builds on the strength of that foundation and advances our ambition to be the leading immunology innovator of the future. The addition of FB102 to our portfolio aligns perfectly with the argenx playbook: compelling biology, strong clinical validation and broad potential to address patient need. I am grateful to the Forte Biosciences team for their outstanding work. Together, we look forward to unlocking the full potential of FB102 and accelerating its impact for patients.”

Also Read: Inocras and AimedBio Partner for Cancer Drug Discovery

“We are incredibly proud of what we have achieved in advancing FB102 through clinical development and firmly believe that argenx is the ideal strategic partner to unlock the full potential of this novel anti-CD122 antibody across a broad range of autoimmune diseases,” said Paul A. Wagner, Ph.D., Chief Executive Officer and Chairperson of the Board of Forte Biosciences. “By combining FB102’s promising clinical profile with argenx’s proven development expertise, global reach and commercial capabilities, we have a unique opportunity to accelerate its development and maximize its impact for patients living with vitiligo, celiac disease, alopecia areata and other autoimmune conditions. We are excited about the future of FB102 and the potential to bring this innovative therapy to many more patients worldwide.”

Forte Biosciences recently reported positive Phase 1b data in vitiligo, demonstrating statistically significant treatment benefit. In addition, positive FB102 Phase 1b data in celiac disease was shared last year, with Phase 2 data expected in the second half of this year. These studies were key drivers of argenx’s decision to move from strategic investment to acquisition, providing clinical evidence in indications with significant unmet need and limited treatment options. Beyond celiac disease and vitiligo, FB102 has the potential to address alopecia areata and additional autoimmune diseases, supporting its profile as a potential pipeline-in-a-product opportunity.

FB102 complements argenx’s existing portfolio of antibody-based programs, including efgartigimod, empasiprubart, adimanebart, and ARGX-121, as well as several additional early-stage molecules, by adding a mechanism focused on pathogenic T-cell and NK-cell activity, broadening the company’s ability to pursue diseases driven by different dimensions of the immune system.

Source: BusinessWire

The post argenx to Acquire Forte Biosciences, Inc., Adding First-in-Class Anti-CD122 Antibody, FB102, to Its Immunology Pipeline appeared first on ITDigest.

Also Read: Catalent Launches Qai to Transform Manufacturing QA

This entry-level initiative offers bundled licensing options which fit the growth pattern of companies at the pre-series and venture-backed stages, allowing start-ups to scale as their research portfolios grow without a hiccup. Highlighting the strategic value of this digital foundation for early-stage innovators, Kevin Willoe, president of Revvity Signals Software, stated: “Signals for Startups addresses a critical need for emerging biotech companies that want to move fast without creating data and workflow challenges that limit their ability to scale. By combining startup-friendly access with guided onboarding and scalable Signals workflows, we are helping early-stage teams build the digital foundation they need to advance discovery, support investor readiness and grow with confidence.” Slated for release in late July 2026 across the United States, Europe, the Middle East, and Africa, Signals for Startups empowers emerging life sciences ventures to establish robust data governance, support investor readiness, and maintain long-term competitive agility.

Read More: Revvity Launches “Signals for Startups” to Help Emerging Biotechs Build Scalable Digital Foundations from Day One

The post Revvity Launches “Signals for Startups” to Empower Early-Stage Biotechs appeared first on ITDigest.